(800)525-7111 Free Consultation

Zantac Cancer Risk and Recall for NDMA

Riddle Brantley LLP   |  October 1, 2019   |  

Does Zantac cause cancer?

***UPDATE: As of April 2020, the FDA has ordered all manufacturers to stop selling Zantac and ranitidine based on significant risk that NDMA-contaminated Zantac may cause cancer.

With evidence indicating a possible cancer risk, in late 2019 Walgreens, CVS and Rite-Aid proactively stopped selling Zantac and ranitidine, a generic version of the popular heartburn medication.

Many people are asking “I heard the Zantac I’ve been taking could cause cancer. Is that true?”

According to a review by the Food & Drug Administration (FDA), Zantac may contain NDMA, a dangerous substance that may cause cancer.

In a statement, the FDA said that some ranitidine medications, including Zantac, contain low levels of ranitidine.

“NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests.”

-Food & Drug Administration (FDA)

Zantac is manufactured by Sanofi and is one of the most common medications for preventing and treating heartburn.

Zantac Recall

Does Zantac Cancer RisksZantac has been recalled by Zantac and ranitidine manufacturers by order of the FDA, and the FDA has recommended that patients stop taking the heartburn medication as well as generic equivalents containing ranitidine.

Beyond Zantac, a voluntary recall was previously issued by Sandoz, a manufacturer that makes ranitidine hydrochloride capsules. The drug maker issued the recall after contamination by the potentially cancer-causing substance was confirmed.

Are You Taking Zantac? Have You Been Diagnosed with Cancer? 

FEBRUARY 2023 UPDATE: Due to developments in the litigation, at this time we can no longer accept additional Zantac claims. Please stay tuned to our website for the latest information and updates. 

If you’re taking or have taken brand-name Zantac and have been diagnosed with cancer, contact the Zantac lawsuit lawyers at Riddle & Brantley.

Patients who have taken brand-name Zantac and been diagnosed with cancer deserve justice — and may be entitled to financial compensation.

Potential cancers that may qualify you for a Zantac cancer lawsuit include:

IMPORTANT: A federal judge recently ruled against lawsuits concerning generic Zantac. At this point, we can only accept cases concerning use of brand-name Zantac OR “mixed” use of brand-name Zantac and generic equivalents.

PLEASE NOTE: At this time, the federal MDL has limited the Zantac claims we can accept to bladder, esophageal, stomach, liver, and pancreatic cancers only. We understand that other cancers may be linked, but we are unfortunately unable to assist with these claims at this time due to evidence and recent court rulings.

We have more than 220+ years of combined experience holding drug manufacturers accountable for medications that endanger patient safety.

Please call 1-800-525-7111 for a FREE consultation or complete the form below.

Zantac Lawsuit Lawyers - Riddle & BrantleyThere are no upfront costs and no attorney fees unless we win your case and you receive financial compensation.

Call 1-800-525-7111 to speak with a Zantac cancer lawyer today.

FEBRUARY 2023 UPDATE: Due to developments in the litigation, at this time we can no longer accept additional Zantac claims. Please stay tuned to our website for the latest information and updates. 

The case review is free. We will listen to you, advise you on your legal options, and help you determine the best path forward.

If you’re concerned about Zantac cancer risks or suffered from cancer potentially caused by Zantac or other possibly NDMA-contaminated medications, you deserve justice and may be entitled to significant compensation.

Call Riddle & Brantley today at 1-800-525-7111.

Justice Counts, and we’re here to help.


***Disclaimer: No settlement agreement has been reached in any litigation regarding ranitidine (ZANTAC®), including in the Multidistrict Litigation in the United States District Court for the Southern District of Florida (case no. 20-MD-2924).